The use of levosimendan in shocked patients with compromised left ventricular function and requiring catecholamine support - A case series

Critical Care and Shock

Volumn 8, Issue 1, 2005, Pages 6-13

  McLean, Anthony S ^a   Nalos, Marek ^a   Huang, Stephen J ^a   Ting, Iris ^a  

^a UNIVERSITY OF SYDNEY   (Australia)

Author keywords

Acute heart failure; B type natriuretic peptide; Case series; Levosimendan; Sepsis; Shock

Indexed keywords

BRAIN NATRIURETIC PEPTIDE; CALCIUM; CATECHOLAMINE; HEPARIN; INOTROPIC AGENT; LACTIC ACID; LEVOSIMENDAN; NORADRENALIN;

ADULT; AGED; ARTICLE; CALCIUM BLOOD LEVEL; CARDIOGENIC SHOCK; CLINICAL ARTICLE; DOSE RESPONSE; DRUG SAFETY; FEMALE; HEART HEMODYNAMICS; HEART LEFT VENTRICLE EJECTION FRACTION; HEART LEFT VENTRICLE FAILURE; HEPARIN INDUCED THROMBOCYTOPENIA; HUMAN; INTENSIVE CARE UNIT; LACTATE BLOOD LEVEL; MALE; MEAN ARTERIAL PRESSURE; RETROSPECTIVE STUDY; SIDE EFFECT; TEACHING HOSPITAL;

EID: 14944382604     PISSN: 14107767     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (29)

1. Landry DW, Oliver JA (2001) The pathogenesis of vasodilatory shock. N Engl J Med 345: 595-599.
2. Goldstein JA (2003) Right versus left ventricular shock. J Am Coll Cardiol 41:1280-1282.
3. Krishnagopalan S, Kumar A, Parrillo JE, Kumar A (2002) Myocardial dysfunction in the patient with sepsis. Curr Opin Crit Care 8:376-388.
4. Dellinger RP (2003) Cardiovascular management of septic shock. Crit Care Med 31:946-955.
5. Cowley AJ, Skene AM (1994) Treatment of severe heart failure: quantity or quality of life? A trial of enosimone. Enoximone Investigators. Br Heart J 72:226-230.
6. Ince C, Sinaasappel M (1999) Microcirculatory oxygenation and shunting in sepsis and shock. Crit Care Med 27:1369-1377
7. Elis A, Betal T, Kimchi O, Ravid M, Lishner M (1998) Intermittent dobutamine treatment in patients with chromic refractory congestive heart failure: A randomised, double blind, placebo-controlled study. Clin Pharmacol Ther 63:682-685.
8. Cohn JN, Goldstein SO, Greenberg BH, Lorell BH, Bourge RC, Jaski BE, Gottlieb SO, McGrew F, DeMets DL, White BG (1998) A dose-dependent increase in mortality with vesnarinone among patients with sever heart failure. Vesnarinone Trial Investigators. N Engl J Med 339:1810-1816.
9. Cleland JG, McGowan J (2002) Levosimendan: A new era for inodilator therapy for heart failure. Curr Opin Cardiol 17:257-265.
10. + channel in rat ventricular cells. J Pharmacol Exp Ther 283:375-383.
11. Haikala H, Kaivola J, Nissinen E, Wall P, Levijoki J, Linden IB (1995) Cardiac troponin C as a target protein for a novel calcium sensitising drug, levosimendan. J Mol Cell Cardiol 27:1859-1866.
12. Haikala H, Linden IB (1995) Mechanisms of action of calcium-sensitizing drugs. J Cardiovasc Pharmacol 26(Suppl 1):S10-19.
13. + channel opening: a new drug principle in cardiovascular medicine. Heart 76:109-116.
14. Lilleberg J, Nieminen MS, Akkila J, Heikkila L, Kuitunen A, Lehtonen L, Verkkala K, Mattila S, Salmenpera M (1998) Effects of a new calcium sensitizer, levosimendan, on hemodynamics, coronary blood flow and myocardial substrate utilization early after coronary artery bypass grafting. Eur Heart J 19:660-668.
15. McLean AS, Tang B, Nalos M, Huang SJ, Stewart DE (2003) Increased B-type natriuretic peptide (BNP) level is a strong predictor for cardiac dysfunction in intensive care unit patients. Anaesth Inten Care 31:21-27.
16. Slawsky MT, Colucci WS, Gottlieb SS, Greenberg BH, Haeusslein E, Hare J, Hutchins S, Leier CV, LeJemtel TH, Loh E, Nicklas J, Ogilby D, Singh BN, Smith W (2000) Acute hemodynamic and clinical effects of levosimendan in patients with severe heart failure. Circulation 102:2222-2227.
17. McLean AS, Huang SJ, Nalos M, Tang B, Stewart DE. (2003) The confounding effects of age, gender, serum creatinine and electrolytes concentrations on plasma B-type natriuretic peptide levels in the critically ill patients. Crit Care Med 31:2611-2618.
18. Nakagawa O, Ogawa Y, Itoh H, Suga S, Komatsu Y, Kishimoto I, Nishino K, Yoshimasa T, Nakao K (1995) Rapid transcriptional activation and early mRNA turnover of BNP in cardiocyte hypertrophy: evidence for BNP as an "emergency" cardiac hormone against ventricular overlaod. J Clin Invest 96:1280-1287.
19. Witthaut R, Busch C, Fraunberger P, Walli A, Seidel D, Pilz G, Stuttmann R, Speichermann N, Verner L, Werdan K (2003) Plasma atrial natriuretic peptide and brain natriuretic peptide are increased in septic shock: impact of interleukin-6 and sepsis-associated left ventricular dysfunction. Intensive Care Med 29:1696-1702.
20. Poelaert J, Declerck C, Vogelaers D, Colardyn F, Visser CA (1997) Left ventricular systolic and diastolic function in septic shock. Intensive Care Med 23:553-560.
21. Delle Karth G, Buberl A, Geppert A, Neunteufl T, Huelsmann M, Kopp C, Nikfardjam M, Berger R, Heinz G (2003) Hemodynamic effects of a continuous infusion of levosimendan in critically ill patients with cardiogenic shock requiring catecholamines. Acta Anaesthesiol Scand 47:1251-1256.
22. Kazanegra R, Cheng V, Garcia A, Krishnaswamy P, Gardetto N, Clopton P, Maisel A. (2001) A rapid test for B-type natriuretic peptide correlates with falling wedge pressures in patients treated for decompensated heart failure: A pilot study. J Card Failure 7:21-29.
23. Oldner A, Konrad D, Weitzberg E, Rudehill A, Rossi P (2001) Effects of levosimendan, a novel inotropic calcium-sensitizing drug, in experimental septic shock. Crit Care Med 29:2185-2193.
24. Behrends M, Peters J (2003) The calcium sensitizer levosimendan attenuates endotoxin-evoked myocardial dysfunction in isolated guinea pig hearts. Intensive Care Med 29:1802-1807.
25. Mizock BA, Falk JL. Lactic acidosis in critical illness (1992) Crit Care Med 20:80-93.
26. Levraut J, Ciebiera JP, Chave S, Rabary O, Jambou P, Carles M, Grimaud D (1998) Mild hyperlactatemia in stable septic patients is due to impaired lactate clearance rather than overproduction. Am J Resp Crit Care Med 157:1021-1026.
27. De Backer D, Creteur J, Preiser J-C, Dubois MJ, Vincent JL (2002) Microvascular blood flow is altered in patients with sepsis. Am J Respir Crit Care Med 166:98-104.
28. Crouser ED, Julian MW, Blaho DV, Pfeiffer DR (2002) Endotoxin-induced mitochondrial damage correlates with impaired respiratory activity. Crit Care Med 30:276-284
29. Vincent JL, de Mendonca A, Cantraine F, Moreno R, Takala J, Suter PM, Sprung CL, Colardyn F, Blecher S (1998) Use of SOFA score to assess the incidence of organ dysfunction/failure in intensive care units: Results of a multicentre, prospective study. Crit Care Med 26:1793-1800.